Table 3 Adverse events reported by interventional investigators
Event | MSC group (N = 99) | Control group (N = 99) | ||
|---|---|---|---|---|
Any grade | Grade ≧ 3 | Any grade | Grade ≧ 3 | |
Any adverse event | 92 (92.9) | 83 (83.8%) | 95 (96.0%) | 85 (85.9%) |
Hematologica | – | 37 (37.4%) | – | 53 (53.5%) |
Platelets decreased | – | 21 (21.2%) | – | 30 (30.3%) |
Neutrophils decreased | – | 16 (16.2%) | – | 23 (23.2%) |
Skinb | 27 (27.3%) | 8 (8.1%) | 32 (32.3%) | 12 (12.1%) |
Gastrointestinalb | 30 (30.3%) | 5 (5.1%) | 37 (37.4%) | 8 (8.1%) |
Hepatobilinary or pancreaticb | 16 (16.2%) | 5 (5.1%) | 18 (18.2%) | 4 (4.0%) |
Cardiac | 39 (39.4%) | 13 (13.1%) | 41 (41.4%) | 16 (16.2%) |
Renal or genitourinary | 27 (27.3%) | 10 (10.1%) | 28 (28.3%) | 11 (11.1%) |
Vascular | 18 (18.2%) | 7 (7.1%) | 19 (19.2%) | 10 (10.1%) |
Infections | 75 (75.8%) | 65 (65.7%) | 81 (81.8%) | 78 (78.8%) |
Secondary malignant disease | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |